Do you want to link to this External Website and leave


Amgen Europe takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Value-Based Partnerships

By engaging in value-based programmes and collaborations that support proactive and preventive care, Amgen is working to improve sustainability and efficiencies in healthcare systems, while advancing patient and population outcomes.

Unlocking Value for the Healthcare System

Amgen’s value-based partnerships identify mutually beneficial opportunities to unlock value for the healthcare system and society worldwide. We believe that value-based partnerships are the key to unlocking real possibilities to improve healthcare provision and outcomes.

Creating a more sustainable high-quality healthcare system will require transformative change to a value-based healthcare model where the focus shifts from short-term budgeting and spending on inputs to one that’s concentrated on quality, efficiency and improving patient outcomes.

Key to success with a value-based healthcare model that reduces costs, improves care and enhances patient experiences is collaboration between organizations who recognize each other’s complementary expertise, experience and capabilities.

These collaborative working relationships are known by Amgen as value-based partnerships: two or more organizations sharing a mutually beneficial endeavor to deliver the highest value to the healthcare system and patients by focusing on improving patient outcomes while lowering system and societal total costs.

Amgen has already made a conscious shift from the traditional industry position of being a transactional supplier of medicines and is prioritizing funding for activities that make us a collaborative partner within the healthcare ecosystem.

Opportunities for value-based partnerships can be found across the healthcare system. Examples are:

  • Disease management programs to help improve patient, caregiver or healthcare practitioner (HCP) awareness
  • Patient/caregiver initiatives to support active treatment management and adherence
  • Patient identification initiatives/predictive analytics/risk stratification programs to identify patients in underdiagnosed areas
  • Electronic Medical Record (EMR) initiatives and tech-based solutions that use software to address gaps in care
  • Population studies and scientific publication using medical or claims data
  • Data sharing/integration of data sources for mutual benefit

Meaningful Improvement

  • Amgen is investing in more than 110 value-based partnerships in Europe across 21 countries including 36 in bone, 33 in cardiovascular, 31 in oncology and 7 in areas such as inflammation and nephrology.
  • Our partnerships are helping to enhance patients’ experience and improve outcomes resulting in meaningful improvements in some of the most challenging disease areas. Our innovative approach touches the lives of 164,000 patients in Europe with a projected future reach of 1.2 million throughout the duration of our partnerships.

Examples of Successful Partnerships to Date


Applying molecular testing to enable precision medicine and RAS gene testing and minimal residual disease (MRD) testing

Overview: Key oncology centers and hospitals in the UK, Germany, France and Spain conducting in-center testing for the RAS gene mutation found in cancers such as metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC).

Key Takeaway: Dramatic decrease in turn-around time in the UK for RAS mutation status analysis in mCRC, from an average of 27 days to 2-3 days, surpassing the original target of a 30 per cent reduction, with this testing model now recognized as best practice. Implementing this technology delivered shortened timelines including faster tissue analyses with faster turn-around time, speedier diagnosis and decisions about appropriate therapy initiation.

We are also driving standardization of testing for MRD, a new surrogate endpoint for Progression Free Survival (PFS) in acute lymphoblastic leukemia (ALL), and newly diagnosed multiple myeloma (NDMM) patients via a centralized network of laboratories in Italy and Spain. Establishing rapid MRD assessment in participating hospitals has resulted in optimized and risk-driven therapeutic decision-making and improved quality of care for patients.

Insights from these programmes led to further innovative solutions to support cancer patients beyond their therapy including:

MiMomento partnership with academic hospitals, psycho-oncologists and patients in Spain leveraging a newly co-developed mindfulness app to address the high prevalence of anxiety and depression in patients with multiple myeloma.

Home infusion programs in Sweden, Italy and France providing installation of an easy-to-use pump system to allow patients to perform one of their twice-weekly infusions from home, reducing patient stress and travel time while reducing the administrative burden on hospital staff.


Using AI to improve patient risk stratification and prediction - CV AI

Overview: Harnessing the power of data, Amgen uses AI and machine learning to improve patient identification, optimize clinical development to improve risk stratification in Myocardial infarction (MI) patients and identify what drives individual risk and how treatment can be optimized. We plan to scale the approach by testing an algorithm in Real World Data (RWD).

Key Takeaway: Ambition to use cross-validated outcomes from clinical trials and RWD insights to better predict
post-MI patients with most urgent need to treat. Plan to scale approach to other areas of unmet need including bone metastasis, multiple myeloma and NSCLC.

Insights from our approach to Innovation have led to further innovative solutions to support post-MI patients beyond their therapy including:

  • CV pathway optimization in three countries to establish a new standard of care for post-MI patients with the potential to scale throughout Europe.
  • Fhabian digital care pathway partnership to develop innovative IT solution for cascade screening, sampling, diagnosis, treatment and follow-up of patients with familial hypercholesterolemia (FH), working with Karolinska University Hospital, FH Centre of Excellence and Health Solutions.


Strengthening ecosystem for post fracture care - Capture the Fracture

Overview: Partnership with International Osteoporosis Foundation, University of Oxford and UCB to implement framework for fracture liaison services across 17 countries by the end of 2021. The Capture the Fracture® Partnership proactively implements post-fracture care coordination programs in hospitals and healthcare systems, to help prevent subsequent fractures due to osteoporosis, and improve patient care. With the aim of reducing the incidence of hip and vertebral fractures due to osteoporosis by 25% by 2025, the program provides virtual and in-person local mentorship and learning and driving policy change.

Key Takeaway: 500+ post-fracture care programs across 17 countries worldwide with 55% increased number of patients reached and 50% increase in post-fracture treatment rates by 2021. Fracture Liaison Service programs have already been initiated in nine countries across Europe.

Insights from these programs led to further innovative solutions to support osteoporosis patients beyond their therapy including:

  • Zebra machine learning approach to review CT scans to identify previously undiagnosed vertebral compression fractures for earlier detection of osteoporosis.
  • Crystal Bone fracture risk prediction algorithm applying machine learning to provide diagnostic measurements to reduce hospitalisation and improve treatment.
  • Partnership with the Italian Association of Medical Oncology and Europa Donna to implement coordinated, multi-disciplinary care pathways in order to prevent fragility fractures in patients with breast cancer treated with adjuvant endocrine therapy.
  • Exciting new partnership with a major player in audiology to drive self-activation, referral, diagnosis and treatment of women aged over 65 with low bone mineral density who are potentially at dual risk of fragility fractures and hearing loss.